Sun Pharma signs global licensing deal for cholesterol drug Lerodalcibep
By United One News · AI-generated summary of 1 outlets' reporting
Published
AI-generated summary of the coverage listed below:
- Sun Pharma has entered a global licensing agreement with LIB Therapeutics for Lerodalcibep, a once‑monthly PCSK9 inhibitor that lowers LDL‑C and treats adult hypercholesterolaemia and mixed dyslipidaemia.
- The partnership expands access to the drug worldwide.
Covered by 1 outlet across the spectrum: 0% left, 100% center, 0% right.
How each side framed it
Sun Pharma inks global licensing pact with LIB Therapeutics for cholesterol drug Lerodalcibep
Timeline
First reported by The Hindu BusinessLine on ; 1 article from 1 outlets so far.
Who is covering this story
- Center (1): The Hindu BusinessLine